Citi initiated coverage of Morphic Therapeutic with a Buy rating and $46 price target. Morphic is a clinical staged biotech focused on discovering and developing integrin inhibitors, the analyst tells investors in a research note. The firm says FDA approval of Entyvio validated alpha-4beta7 inhibition as an effective mechanism of action in inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. Citi sees favorable risk/reward profile into the topline Phase 2b EMERALD-2 data expected in the first half of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MORF:
- TD Cowen starts ‘only pure-play TL1A company’ Spyre Therapeutics at Outperform
- Morphic price target lowered to $76 from $80 at RBC Capital
- Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
- Morphic expects cash to fund operations through second half of 2027
- Morphic reports Q3 EPS (73c), consensus (95c)